BioSpace News Archive

MYOS RENS Technology Inc. (“MYOS” or the “Company”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin ® , a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle, announced that it has settled its pending litigation with RENS Technology Inc. and its president,

Alpha Health Inc, the first Unified Automation company for healthcare, announced today its paper describing the company’s method of using a neural network to predict health care billing claim denials will be featured as a spotlight session during the Healthcare Systems, Population Health and the Role of Health-Tech Workshop

Signify Health, a leading provider of technology-enabled healthcare solutions designed to keep people healthy and happy at home, announced today two executive appointments to its Episodes of Care (EOC) Division.

CDC’s latest emergency use authorization for influenza SARS-CoV-2 assay validates Quantabio’s ability to multiplex up to five targets with high efficiency, sensitivity and specificity BEVERLY, Mass.--( BUSINESS WIRE )-- Quantabio , a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced that its UltraPlex 1-Step ToughMix was recognized as part

Halberd Corp. (OTC PINK: HALB ) intends to use laser technology to eradicate the COVID-19 Coronavirus. This patent pending treatment introduces one or more fluorescent antibody-antigen complexing agents to bind with the target antigen(s) (i.e., Covid-19 target antigens). This will allow the virus to be seen and located, and allow for eradicating the fluorescent antibody-antigen complex by utilizing an energy burst from a nano-laser, with the re

Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, announced the expansion of patient enrollment in its Phase 1 clinical trial evaluating eprenetapopt in TP53 mutant AML.

Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities

Detailed results from the positive Phase III THALES trial showed AstraZeneca’s BRILINTA® 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17%, compared to aspirin alone in patients who had an acute ischemic stroke or transient ischemic attack.

Oncorus Announces Clinical Trial Collaboration with Merck to Evaluate the Combination of Oncorus’ ONCR-177 with Merck’s KEYTRUDA® (pembrolizumab) in Adult Patients with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors

Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, and has a Phase 2 ready norovirus vaccine program, today announced that a new study was published in the Journal of Infectious Diseases today, which concluded that norovirus gastroenteritis costs the United States an estimated median of $10.6 billion each year. In part